Stock Market & Financial Investment News

News Breaks February 8, 2013 15:37 EDT CELG, ONXX FDA announces approval of Celgene multiple myeloma treatment The FDA said it approved Celgene's (CELG) Pomalyst to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs. In July 2012, the FDA approved Kyprolis to treat multiple myeloma. The FDA said that similar to Onyx Pharmaceuticals' (ONXX) Kyprolis, Pomalyst is being approved under the agency’s accelerated approval program, which provides patients earlier access to promising new drugs while the company conducts additional studies to confirm the drug’s clinical benefit and safe use. The therapy was also granted orphan product designation because it is intended to treat a rare disease or condition. Pomalyst carries a Boxed Warning alerting patients and health care professionals that the drug should not be used in pregnant women because it can cause severe life-threatening birth defects, and that the drug can cause blood clots. Because of Pomalyst’s embryo-fetal risk, it is available only through the Pomalyst Risk Evaluation and Mitigation Strategy Program. News For CELG;ONXX From The Last 14 Days Check below for free stories on CELG;ONXX the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 24, 2013 07:20 EDT CELG Celgene, Gilead, and Biogen could go much higher, says Bernstein Subscribe for More Information May 23, 2013 07:37 EDT CELG Celgene says FDA grants priority review for ABRAXANE sNDA Subscribe for More Information May 21, 2013 13:36 EDT ONXX Onyx Pharmaceuticals mentioned cautiously at BofA/Merrill Subscribe for More Information May 20, 2013 09:51 EDT CELG Celgene management to meet with JPMorgan Meetings to be held in Boston on May 22-23 hosted by JPMorgan. May 17, 2013 05:51 EDT CELG Stocks with implied volatility movement; CBST CELG Subscribe for More Information May 16, 2013 11:50 EDT CELG Celgene, Gilead lower after new data published at ASCO Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.